Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05750914 · ClinicalTrials.gov registry record · NA
Evaluation of Broadband Light Treatment for Pigmented Skin Lesions
A NA study, sponsored by Sciton.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT05750914: Completed NA study, sponsored by Sciton.
NCT05750914 is a NA study that has completed, run by Sciton. The registered enrollment target is 15 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05750914, a NA study, has completed, sponsored by Sciton.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
Evaluation of safety and efficacy of Broadband light treatment
Primary Outcome
Percent improvement in pigmentation as assessed using digital photographs taken at baseline and 4-6 weeks post treatment
Interventions
- DEVICE Broadband Light
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2024-01-19 |
| Phase | NA |
What the finished NCT05750914 record still lists
NCT05750914 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Broadband Light is the first listed.
NCT05750914 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05750914 about?
NCT05750914 is a clinical study titled "Evaluation of Broadband Light Treatment for Pigmented Skin Lesions". Evaluation of safety and efficacy of Broadband light treatment
What is the current status of trial NCT05750914?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2022-09-01. Estimated completion is 2024-01-19.
What interventions are being tested in trial NCT05750914?
The interventions under investigation include: Broadband Light (DEVICE).
Who is sponsoring clinical trial NCT05750914?
This trial is sponsored by Sciton, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05750914's enrollment target sits among peer trials
15 1881st of 2000 higher than 92 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI